Back to Search
Start Over
Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.
- Source :
-
Pharmacogenomics [Pharmacogenomics] 2018 Oct; Vol. 19 (15), pp. 1203-1216. Date of Electronic Publication: 2018 Sep 10. - Publication Year :
- 2018
-
Abstract
- Current guideline recommendations for pharmacogenetic testing for clopidogrel by the American Heart Association/American College of Cardiology (AHA/ACC) contradict the Clinical Pharmacogenetics Implementation Consortium and the US FDA. The AHA/ACC recommends against routine pharmacogenetic testing for clopidogrel because no randomized controlled trials have demonstrated that testing improves patients' outcomes. However the AHA/ACC and the National Comprehensive Cancer Network (NCCN) recommend other pharmacogenetic tests in the absence of randomized controlled trials evidence. Using clopidogrel as a case example, we compared the evidence for other pharmacogenetic tests recommended by the AHA/ACC and NCCN. In patients that received percutaneous coronary intervention, the evidence supporting pharmacogenetic testing for clopidogrel is stronger than other pharmacogenetic tests recommended by the AHA/ACC and NCCN.
Details
- Language :
- English
- ISSN :
- 1744-8042
- Volume :
- 19
- Issue :
- 15
- Database :
- MEDLINE
- Journal :
- Pharmacogenomics
- Publication Type :
- Academic Journal
- Accession number :
- 30196751
- Full Text :
- https://doi.org/10.2217/pgs-2018-0097